Literature DB >> 7689097

Disposition of recombinant human granulocyte colony-stimulating factor in children with severe chronic neutropenia.

C M Kearns1, W C Wang, N Stute, J N Ihle, W E Evans.   

Abstract

The disposition of recombinant human granulocyte colony-stimulating factor (G-CSF) was studied in 11 children with severe chronic neutropenia given 6 to 48 micrograms G-CSF per kilogram subcutaneously. Serum concentrations of G-CSF were measured by bioassay. Peak serum G-CSF concentrations were proportional to dosage and occurred 2 to 8 hours after subcutaneous administration. Nine of the eleven children had a significant increase in absolute neutrophil count (ANC). The median ANC in responding patients was 6.7 x 10(9)/L on day 14 versus 0.17 x 10(9)/L on day 1 of therapy (p < 0.01). The G-CSF clearance increased as ANC increased, and the relationship was well described by a sigmoid model. Maximal clearance approached 2 ml/min per kilogram at ANCs > 17.0 x 10(9)/L; minimal clearance was 0.29 ml/min per kilogram at ANCs of 0. The half-life of G-CSF was inversely related to ANC; mean half-life was 4.7 hours at ANCs of 0 but < 2 hours at ANCs greater than 17.0 x 10(9)/L. The two patients who failed to achieve a clinical response had no change in G-CSF clearance or half-life, nor did they have an increase in ANC when G-CSF dosages were escalated to 18 or 48 micrograms/kg twice a day. These results indicate that G-CSF pharmacokinetics are directly influenced by ANC; higher serum concentrations, slower clearances, and longer half-lives are associated with low ANCs.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7689097     DOI: 10.1016/s0022-3476(05)81760-3

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  9 in total

1.  Pharmacokinetics of glycosylated recombinant human granulocyte colony-stimulating factor (lenograstim) in healthy male volunteers.

Authors:  A C Houston; L A Stevens; V Cour
Journal:  Br J Clin Pharmacol       Date:  1999-03       Impact factor: 4.335

2.  A mathematical model for reconstitution of granulopoiesis after high dose chemotherapy with autologous stem cell transplantation.

Authors:  Ivar Østby; Leiv S Rusten; Gunnar Kvalheim; Per Grøttum
Journal:  J Math Biol       Date:  2003-04-23       Impact factor: 2.259

Review 3.  Pharmacokinetic studies with recombinant cytokines. Scientific issues and practical considerations.

Authors:  S C Piscitelli; W G Reiss; W D Figg; W P Petros
Journal:  Clin Pharmacokinet       Date:  1997-05       Impact factor: 6.447

4.  Effects of renal function on pharmacokinetics of recombinant human granulocyte colony-stimulating factor in lung cancer patients.

Authors:  M Fukuda; M Oka; Y Ishida; H Kinoshita; K Terashi; M Fukuda; S Kawabata; A Kinoshita; H Soda; S Kohno
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

Review 5.  Pharmacokinetics and pharmacodynamics of pegfilgrastim.

Authors:  Bing-Bing Yang; Anna Kido
Journal:  Clin Pharmacokinet       Date:  2011-05       Impact factor: 6.447

Review 6.  Dynamic hematological disease: a review.

Authors:  Catherine Foley; Michael C Mackey
Journal:  J Math Biol       Date:  2008-03-04       Impact factor: 2.259

Review 7.  Filgrastim. A review of its pharmacological properties and therapeutic efficacy in neutropenia.

Authors:  J E Frampton; C R Lee; D Faulds
Journal:  Drugs       Date:  1994-11       Impact factor: 9.546

8.  Durable multitransgene expression in vivo using systemic, nonviral DNA delivery.

Authors:  Chakkrapong Handumrongkul; Alice L Ye; Stephen A Chmura; Liliana Soroceanu; Marissa Mack; Ryan J Ice; Robert Thistle; Methawee Myers; Sarah J Ursu; Yong Liu; Mohammed Kashani-Sabet; Timothy D Heath; Denny Liggitt; David B Lewis; Robert Debs
Journal:  Sci Adv       Date:  2019-11-27       Impact factor: 14.136

Review 9.  Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma.

Authors:  Claudio Cerchione; Davide Nappi; Giovanni Martinelli
Journal:  Support Care Cancer       Date:  2021-05-14       Impact factor: 3.603

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.